Verthermia provides the fourth modality of cancer treatment which induces Whole Body Hyperthermia (WBHT) by directly heating circulating blood. Stand alone or as an adjunct to chemotherapy radiation.
Verthermia, based in California, develops the only effective cancer treatment which induces whole body hyperthermia (WBH) by directly heating and cooling the body core evenly and consistently, branded as Hyperthermic Extracorporeal Applied Tumor Therapy – HEATT™.
Answering the call for the fourth modality in cancer treatment, the company provides equipment and disposables for the treatment of cancer, either alone or as an adjunct to chemo and radiation. Technologies are based on founders’ prior experiences using WBH to treat lung cancer, ovarian cancer and infectious diseases (HIV/AIDS). Currently engaged in a FDA approved metastatic ovarian cancer Phase I clinical trial. First patients trials completed in San Jose, CA with next trials moving ahead at the Cleveland Clinic.
Expected approval and product launch in 12 to 18 months with over 100 major cancer centers expected to rapidly adopt the technology.
2nd & 3rd Gen Filtration (Multiple Disease Targets)
Prototype for Fully Automated Blood Chemistry
Patient Portfolio at 100
Complete Clinical Trial for Ovarian Cancer at New Site (Cleveland Clinic)